Latest News & Insights
Stay Up to Date with Our Community
Featured
Westlake BioPartners leads $30 million Series A extension, bringing the startup’s total committed capital to $180 million
Westlake BioPartners leads $30 million Series A extension, bringing the startup’s...
Data to be featured as oral and poster presentations at American...
Former Horizon Therapeutics chairman & CEO brings 30 years of biopharmaceutical...
Digital biomarker to enhance precision, reduce patient burden and boost efficiency...
NEU-411, a brain-penetrant, potent and selective kinase inhibitor, has potential to...
NHP data demonstrate potential for CAP-004 to treat CNS, cardiac, and...
Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration...
Latigo Biotherapeutics, Inc. (“Latigo”) today announced that the first participant has...
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on...